Vivacta Bio完成超过5000万美元的A轮及A+轮融资关闭-动脉网

Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million

PR Newswire 等信源发布 2026-04-29 20:15



可切换为仅中文







Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors

德诚资本、忠谷资本、奥博资本等知名投资者支持

SHANGHAI

上海

，

April 29, 2026

2026年4月29日

/PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ('Vivacta' or 'Vivacta Bio'), an innovative biotechnology company focused on revolutionizing in vivo CAR-T therapies

/PRNewswire/ -- 上海维博特生物科技有限公司（“维博特”或“维博特生物”），一家致力于彻底改变体内CAR-T疗法的创新型生物技术公司

, announces

，宣布

the company recently completed Series A and Series A+ financing of over US$ 50 million. The two series of financing were led by Loyal Valley Capital and Decheng Capital respectively, and participated by renowned investors including OrbiMed, Hankang Capital, Eisai Innovation Inc., C&D Emerging Industry Equity Investment, as well as by existing shareholders such as Qiming Venture Partners, Beijing Shunxi, and Apricot Capital.

公司近期完成了总额超过 5000 万美元的 A 轮与 A+ 轮融资。其中，A 轮和 A+ 轮融资分别由忠诚资本与德诚资本领投，奥博资本、汉康资本、卫材创新、厦钨产投等知名投资机构跟投，现有股东启明创投、北京顺禧、杏泽资本也参与了本轮投资。

Investors in Vivacta's Series A and Series A+ financing comprised global industrial capital and specialist biotechnology investors, whose recognition highlights.

维瓦克塔公司的A轮和A+轮融资投资者包括全球产业资本和专业的生物技术投资者，他们的认可突显了这一点。

the

这

potential of Vivacta's innovative technologies and fuels accelerated clinical development and global operation of the company.

Vivacta的创新技术潜力推动了公司的临床开发加速和全球运营。

'We are deeply honored by the recognition and support from a group of leading investors

“我们深深荣幸得到一群领先投资者的认可和支持

', `

commented Dr. Liu Yarong, Founder and CEO of Vivacta,

刘亚荣博士，Vivacta公司的创始人兼首席执行官评论道，

'Vivacta is committed to advancing innovative in vivo CAR-T cell therapies. Our core product, GT801, has demonstrated promising safety and efficacy profiles in early clinical studies across hematological malignancies and autoimmune disease patients, potentially offering these patient populations a transformative treatment option to deliver innovative therapies to more patients in need.'.

“Vivacta致力于推进创新的体内CAR-T细胞疗法。我们的核心产品GT801在早期临床研究中，针对血液系统恶性肿瘤和自身免疫疾病患者展现了良好的安全性和有效性，有望为这些患者群体提供一种变革性的治疗选择，从而将创新疗法带给更多有需要的患者。”

The proceeds from this financing round will be used to advance clinical trials for GT801, support GT801 regulatory submission and approval, expand research team and build out our platform, and accelerate Vivacta's global expansion in the in vivo CAR-T field. Initial human data of GT801, Vivacta's core project, was recently reported via an oral report at American Society of Hematology Annual Meeting & Exposition 2025 (ASH 2025) in December 2025.

本轮资金将用于推进GT801的临床试验，支持GT801的监管提交与审批，扩大研究团队并构建平台，同时加速Vivacta在全球体内CAR-T领域的扩展。Vivacta核心项目GT801的初步人体数据已在2025年12月举行的2025年美国血液学会年会暨博览会（ASH 2025）上通过口头报告公布。

Upon closing of Series A+ financing, Mr. Xie Ronggang from Loyal Valley Capital and a partner from DC Global Ventures joined the board of directors of Vivacta..

A+轮融资完成后，谢荣刚先生（Loyal Valley Capital）和DC Global Ventures的一位合伙人加入了Vivacta董事会。

About Vivacta

关于Vivacta

Vivacta is a biotechnology company dedicated to pioneering in vivo CAR-T cell therapy, committed to delivering transformative treatments for cancer patients and autoimmune disease patients. The Company's flagship product, GT801, is a next-generation in vivo CAR-T therapy that has shown significant potential in early clinical studies for treating hematologic malignancies and autoimmune conditions..

Vivacta是一家致力于开创体内CAR-T细胞疗法的生物技术公司，专注于为癌症和自身免疫疾病患者提供变革性治疗方案。公司旗舰产品GT801是一种下一代体内CAR-T疗法，在早期临床研究中已显示出治疗血液系统恶性肿瘤和自身免疫疾病的显著潜力。

About DC Global Ventures

关于DC全球风险投资

DC Global Ventures is an investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise to build highly successful companies globally.

DC Global Ventures是一家投资公司，为拥有革命性技术的早期生命科学公司和具有强大市场影响力的成长阶段医疗保健公司提供资金和战略支持。我们是一支由具有互补专业知识的专职人士组成的团队，致力于在全球范围内打造高度成功的公司。

Founded in 2012, DC Global Ventures continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2.5 billion in capital and the support from some of the most prestigious limited partners in the world, DC Global Ventures is poised to create value for our investors and entrepreneur partners..

成立于2012年的DC环球创投继续利用医疗保健行业的快速增长以及生命科学研究的突破所带来的历史性机遇。DC环球创投拥有超过25亿美元的资本，并得到了世界上一些最负盛名的有限合伙人的支持，准备为我们的投资者和企业家伙伴创造价值。

About Loyal Valley Capital

关于忠诚谷资本

Established in 2015, Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in companies positioned to benefit from the secular industry transformations in China. LVC mainly focuses on three key sectors: New Consumer, Healthcare, and Advanced Manufacturing.

忠维资本（LVC）成立于2015年，是一家主题驱动、研究导向的私募股权公司，拥有浓厚的创业文化，专注于投资能够从中国长期行业变革中受益的企业。忠维资本主要聚焦于三大关键领域：新消费、医疗健康和先进制造。

。

We pride ourselves as a trusted influential shareholder by entrepreneurs, relentlessly focused on active value creation and accelerating growth via strategic initiatives through our extensive network of business leaders in China.

我们以成为受企业家信赖的有影响力的股东而自豪，通过我们在中国广泛的商业领袖网络，不懈地专注于积极的价值创造，并通过战略举措加速增长。

Loyal Valley Capital has built a robust portfolio of more than 110 outstanding leading companies nationwide. Our diversified portfolio covers representative companies across sectors, including Junshi Biosciences, Allist Pharmaceuticals, Henlius Biotech, Akeso Biopharma, Innovent Biologics, Caris Therapeutics, LBL Therapeutics, SurgiRobot, CoreMedic, UNISOC, Supcon Technology, EVE Energy, Biyi Space, Avary Holding, RIGOL Technologies, Qiangyi Semiconductor, Bilibili, Pop Mart, ByteDance, Xiaohongshu, and MAOGEPING.

忠旺资本在全国范围内构建了包含110多家优秀领先企业的强大投资组合。我们多元化的投资组合覆盖各行业的代表性企业，包括君实生物、艾力斯制药、复宏汉霖、康方生物、信达生物、科瑞医药、LBL Therapeutics、手术机器人公司、CoreMedic、紫光展锐、中控技术、亿纬锂能、璧一空间、弘毅控股、普源精电、强一半导体、哔哩哔哩、泡泡玛特、字节跳动、小红书和毛戈平。

The firm maintains long-term industrial focus and cross-cycle investment vision, committing to delivering sustainable value creation for entrepreneurs, limited partners and the broader society by backing innovative and high-potential enterprises in key strategic industries..

该公司保持长期的产业聚焦和跨周期的投资视野，致力于通过支持关键战略产业中创新且高潜力的企业，为创业者、有限合伙人以及更广泛的社会创造可持续的价值。

About OrbiMed Advisors LLC

关于奥博资本顾问有限公司

OrbiMed is a leading healthcare investment firm, with over $20 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.

奥博资本是一家领先的医疗保健投资公司，管理着超过2000亿美元的资产。奥博资本通过私募股权基金、公共股权基金和特许权/信贷基金在全球范围内对医疗保健行业进行投资，从初创企业到大型跨国公司均有涉及。奥博资本力求成为首选的资本提供者，提供定制的融资解决方案和广泛的全球团队资源，以帮助建立世界级的医疗保健公司。

OrbiMed's team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets..

奥博资本团队由130多名专业人士组成，分布于纽约、伦敦、旧金山、上海、香港、孟买、赫兹利亚及其他主要全球市场。

For more information, please visit

更多信息，请访问

www.orbimed.com.

www.orbimed.com

Vivacta Contact

维瓦克塔联系方式

Yanwen Zhang

张艳文

Email:

电子邮件：

[email protected]